@article{8740075,
  abstract     = {{Purpose The purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales. Methods We pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales. Results Fifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items. Conclusions The QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study. Implications for Cancer Survivors The availability of this questionnaire will facilitate a standardized and robust assessment of the HRQOL of disease-free cancer survivors.}},
  author       = {{van Leeuwen, Marieke and Kieffer, Jacobien M. and Young, Teresa E. and Aaronson, Neil K. and van de Poll-Franse, Lonneke V. and Annunziata, Maria Antonietta and Arndt, Volker and Arraras, Juan Ignacio and Autran, Didier and Hani, Hira Bani and Chakrabarti, Manas and Chinot, Olivier and Cho, Juhee and da Costa Vieira, Rene Aloisio and Darlington, Anne-Sophie and Debruyne, Philip R. and Dirven, Linda and Doege, Daniela and Eller, Yannick and Eichler, Martin and Friðriksdóttir, Nanna and De Giorgi, Ugo and Gioulbasanis, Ioannis and Hammerlid, Eva and van Hemelrijck, Mieke and Hermann, Silke and Husson, Olga and Jefford, Michael and Johansen, Christoffer and Johnson, Colin and Kjaer, Trille Kristina and Kontogianni, Meropi and Lagergren, Pernilla and Lidington, Emma and Lisy, Karolina and Morag, Ofir and Nordin, Andy and Al Omari, Amal S. H. and Pace, Andrea and De Padova, Silvia and Petranoviæ, Duska and Pinto, Monica and Ramage, John and Rammant, Elke and Reijneveld, Jaap and Serpentini, Samantha and Sodergren, Sam and Vassiliou, Vassilios and Verdonck-de Leeuw, Irma and Vistad, Ingvild and EORTC survivorship questionnaire development group, [missing] and on behalf of the EORTC QLG, [missing]}},
  issn         = {{1932-2259}},
  journal      = {{JOURNAL OF CANCER SURVIVORSHIP}},
  keywords     = {{Oncology (nursing),Oncology,Patient reported outcomes,Health-related quality of life,Cancer survivor,Survivorship questionnaire,Disease-free,Oncology,PATIENT-REPORTED OUTCOMES,LONG-TERM,CLINICAL-TRIALS,BREAST-CANCER,CAUSAL INDICATORS,EORTC QLQ-C30,FOLLOW-UP,IMPACT,SCALE,RELIABILITY}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{1111--1130}},
  title        = {{Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire}},
  url          = {{http://doi.org/10.1007/s11764-021-01160-1}},
  volume       = {{17}},
  year         = {{2023}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: